Schaeffer's 43rd Anniversary Stock Picks in 2024

2 Healthcare Stocks Expected to Skyrocket

Cantor and Roth Capital have high expectations for COLL and STML stocks, respectively

Jun 12, 2018 at 1:32 PM
facebook X logo linkedin

The shares of healthcare concerns Collegium Pharmaceutical Inc (NASDAQ:COLL) and Stemline Therapeutics Inc (NASDAQ:STML) are higher today, thanks to some upbeat analyst attention. Specifically, Cantor Fitzgerald last night initiated coverage of COLL stock with an "overweight" rating and a lofty $40 price target -- representing expected upside of 60% to the equity's Monday close. Likewise, Roth Capital started STML stock with a "buy" endorsement and a $30 price target, which represents a premium of nearly 68% to the biopharma stock's close yesterday.

COLL a Top Pharma Pick at Cantor

Along with AcelRx Pharmaceuticals (ACRX), Collegium Pharmaceuticals stock still has "value to be unlocked," Cantor wrote, calling COLL one of its "top picks." In fact, the brokerage firm said Collegium is "emerging as the new leader in responsible pain treatment," and the shares continue to "trade at a discount" to intrinsic value.

From a sentiment standpoint, the specialty pharma stock is no stranger to upbeat analyst attention. In fact, all six of the analysts following COLL maintain "strong buy" opinions. Plus, the consensus 12-month price target of $33.50 represents expected upside of 26.1% to the security's current price.

On the charts, COLL stock more than tripled from its late-October lows to its early March two-year high of $29.90. Since then, the shares have spent the bulk of 2018 in a sideways channel, with support emerging in the $22 area and resistance in the $26-$27 region. At last check, Collegium stock was up 5.7% at $26.39.

COLL stock chart june 12

Roth Capital Optimistic About Stemline's Lead Asset

Roth Capital said it expects Stemline Therapeutics to "sail smoothly" through a biologics license application (BLA) "and then through M&A, thanks to strengths of its lead asset SL-401." In fact, STML shares touched a four-year high of $20.55 on June 5, after reporting upbeat data on SL-701 and SL-801 at the 2018 American Society of Clinical Oncology (ASCO) annual meeting. The company also said in a statement that its "SL-401 regulatory and pre-launch activities continue to progress," and its timelines remain on track.

STML stock has added 140% in the past year, and has been in a channel of higher highs since the fourth quarter. The shares were last seen 2% higher at $18.25 -- back above their 50-day moving average, which has provided support in 2018, along with its 80-day and 160-day counterparts.

STML stock chart

While all four analysts following STML already deem it worthy of a "strong buy" rating, not everyone is convinced. Short interest represents nearly 9% of the equity's total available float, and would take nearly eight sessions to repurchase, at the stock's average pace of trading. That's plenty of fuel for a short squeeze to push the biopharma stock even higher.


A.I.’s Dirty Little Secret: The Real Power Behind The AI. Boom ✨

Anyone who’s seen the The Matrix movies knows that A.I. needs power.  Lots and lots of power.

If you’ve seen the movie, you also know the grizzly results of the ensuing battle for that power.

Now, Wall Street’s battle for A.I. power won’t go to such extremes. Hopefully?

A.I. needs more power and that means more opportunities for stock traders in the know.

Download your free copy of “The A.I. Revolution: 4 Stocks to Buy Now”!